RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272 · cited 1×
“COX2 can also increase the levels of a plethora of other endothelial growth factors, such as basic fibroblast growth factor (bFGF; also known as FGF2) and platelet-derived growth factor (PDGF), and is required for integrin-mediated endothelial cell spreading and migratio”
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 1×
“In addition to stimulating cyclin D1 gene transcription, oncogenic HRAS G12V also regulates the metabolic stability of the cyclin D1 protein through PI3K-dependent inhibition of glycogen synthase kinase 3β (GSK3β), which is the kinase that is responsible for the phosphorylation and the consequent ubiquitylation and pr…”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Rabinowitz, J. D., & White, E. (2010) · Science · doi:10.1126/science.1193497 · Cited by 1,982
Massagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879 · cited 1×
“A prime example of such an effect is the induction of the outgrowth of new blood vessels, or angiogenesis, which allows cells within the evolving tumour to accommodate the physiological need for an adequate supply of oxygen and nutrient”
BackgroundAn Oncogene-Induced DNA Damage Model for Cancer Development
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851 · cited 1×
“Although OIS is a tumour-constraining response, its induction could contribute to the tumorigenic process by exerting a strong selective pressure in favour of cells in which crucial components of the DNA damage checkpoint have been lost (such as p53 and ARF (also known as p19)”
BackgroundOncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821 · cited 1×
“Thus, the expression of oncogenic RAS reduces the levels of E-cadherin through the upregulation of the E-cadherin transcriptional repressors SNAIL (also known as SNAI1) and SLUG (also known as SNAI2), the stimulation of E-cadherin proteolytic degradation and the induction of E-cadherin promoter methylatio”
BackgroundThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 4×
“Pancreas 0% (278) 57% (5,329) 2% (305) 12 10.”
InfluentialIntegrin signalling during tumour progression
Guo, W., & Giancotti, F. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1490 · Cited by 1,471
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 1×
“This question has been predominantly instigated by the well-recognized non-random distribution pattern of activated isoforms of RAS among the range of cancer type”
BackgroundControl of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Sahai, E., & Marshall, C. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc725 · Cited by 1,261
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., & Evan, G. (1997) · Nature · doi:10.1038/385544a0 · Cited by 1,148 · cited 1×
“For example, the preferential activation of the RAS–RAF–MAPKK–MAPK pathway exacerbates apoptosi”
BackgroundOncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
Tumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085
Dammann, R., Li, C., Yoon, J.-H., Chin, P. L., Bates, S., & Pfeifer, G. P. (2000) · Nature Genetics · doi:10.1038/77083 · Cited by 1,064
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032 · cited 1×
“However, overexpression of cyclin D1 is not sufficient to transform cells without the activity of a cooperating oncogene, pointing to additional RAS-induced mechanisms to provoke a state of proliferative overdriv”
BackgroundSelf-citationA mechanism of repression of TGFbeta / Smad signaling by oncogenic Ras
Kretzschmar, M., Doody, J., Timokhina, I., & Massague, J. (1999) · Genes & Development · doi:10.1101/gad.13.7.804 · Cited by 1,004
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 1×
“One possible mechanism by which oncogenic RAS expression may lead to a compromised antitumour immune response is through the recruitment of immunosuppressive regulatory T cells (T Regs ) and myeloid-derived suppressor cells (MDSCs) to the tumour sit”
BackgroundComplexes of Ras⋅GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase
Moodie, S. A., Willumsen, B. M., Weber, M. J., & Wolfman, A. (1993) · Science · doi:10.1126/science.8503013 · Cited by 968 · cited 1×
“Although initial studies attributed the stimulation of cyclin D1 transcription by oncogenic RAS to the activation of the RAF–MAPK pathway, it has become evident that additional levels of control are executed through RAS activation of PI3Ks, the RHO family GTPase RAC1, and the RAL-guanine nucleotide dissociation stimul…”
BackgroundResnitzky, D., Gossen, M., Bujard, H., & Reed, S. I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1669-1679.1994 · Cited by 965
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 1×
“As such, cyclin D1-deficient mice are resistant to developing mammary cancers and squamous tumours that are induced by the HRAS oncogen”
BackgroundCombined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., & Fuller, G. N. (2000) · Nature Genetics · doi:10.1038/75596 · Cited by 905
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875 · cited 1×
“For example, the elimination of inducible oncogenic HRAS G12V expression results in the regression of melanomas accompanied by massive tumour cell apoptosi”
BackgroundRas-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar-Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 851 · cited 1×
“Several cytokines have been implicated in this response, including interleukin-8 (IL-8), IL-6 and GRO1 (also known as CXCL1), and their RAS-dependent upregulation is predominantly mediated by the activation of signalling pathways that impinge on the transcriptional machinery controlling their expressio”
BackgroundSelf-citationTransforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Richard, D. E., Berra, E., Gothié, E., Roux, D., & Pouysségur, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32631 · Cited by 790
Flier, J. S., Mueckler, M. M., Usher, P., & Lodish, H. F. (1987) · Science · doi:10.1126/science.3103217 · Cited by 786
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777 · cited 1×
“Oncogenic HRAS G12V -mediated upregulation of matrix metalloproteinase 2 (MMP2), MMP9 and urokinase-type plasminogen activator (uPA) has been shown to be instrumental in removing the physical confines of the basement membrane, with upregulation of uPA especially important in potentiating endothelial cell migration and…”
BackgroundRegulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 771
Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression
Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.691 · Cited by 769 · cited 1×
“There is an indication that such a pro-apoptotic function of RAS might be selected against in cancer, as the expression of either RASSF1 or RASSF5 in tumours is frequently suppressed either owing to promoter hypermethylation or — in the case of RASSF1 — owing to the deletion of the chromosomal region that contains the…”
BackgroundRak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 1×
“By contrast, in colorectal and lung cancers, KRAS G12V mutations have been associated with a worse prognosis than KRAS G12D mutations, raising the possibility that particular amino acid substitutions might dictate specific transforming characteristics of oncogenic RAS allele”
BackgroundDe Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730 · cited 1×
“In addition, germline mutations in KRAS and HRAS are associated with the acquisition of distinct developmental disorders ( KRAS is associated with Noonan syndrome and cardio-facio-cutaneous syndrome , and HRAS is associated with Costello syndrome”
BackgroundDiverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
Grünert, S., Jechlinger, M., & Beug, H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1175 · Cited by 678 · cited 1×
“The perturbation of cell–cell contacts by oncogenic RAS is accomplished through the targeting of the molecular machinery that maintains intercellular adhesion junctions, which includes the calcium-dependent E-cadherin receptor and its associated cytoplasmic protein β-cateni”
BackgroundResnitzky, D., Gossen, M., Bujard, H., & Reed, S. I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1669 · Cited by 664
TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
Oft, M., Heider, K.-H., & Beug, H. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00533-7 · Cited by 623 · cited 1×
“RAS activation has also been shown to induce the destabilization of E-cadherin–β-catenin complexes and the relocalization of β-cateni”
BackgroundHaigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601 · cited 1×
“This is achieved through oncogenic RAS-induced concurrent activation of MAPK and PI3K effector pathways leading to the stimulation of mTOR activity and mTOR-mediated cap-dependent translation of HIF1”
BackgroundBiological properties of human c-Ha-ras1 genes mutated at codon 12
Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V., & Levinson, A. D. (1984) · Nature · doi:10.1038/312071a0 · Cited by 585 · cited 1×
“14 ), and it is also more potent in cell culture-based transformation assay”
BackgroundFisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582 · cited 1×
“Additionally, withdrawal of doxycycline-inducible oncogenic KRAS G12D expression from type II pneumocytes causes apoptosis and regression of both early proliferative lesions and lung cancer”
BackgroundFrequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578 · cited 1×
“Likewise, differences in the range of KRAS mutations observed in human tumours of the gastrointestinal tract seemingly reflect variations in the aetiology of RAS mutations as opposed to specific mutation-dependent disease characteristic”
BackgroundTumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 571
Shaw, R. J. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.10.005 · Cited by 550
Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth
Lawler, J. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00307.x · Cited by 540 · cited 1×
“In addition, they directly affect the viability of endothelial cell”
BackgroundChanges in integrin receptors on oncogenically transformed cells
Plantefaber, L. C., & Hynes, R. O. (1989) · Cell · doi:10.1016/0092-8674(89)90902-1 · Cited by 538
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas
Balmain, A., Ramsden, M., Bowden, G. T., & Smith, J. (1984) · Nature · doi:10.1038/307658a0 · Cited by 529
Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
Leone, G., DeGregori, J., Sears, R., Jakoi, L., & Nevins, J. R. (1997) · Nature · doi:10.1038/387422a0 · Cited by 468 · cited 1×
“This suppressive effect is mediated by multiple RAS effector pathways and is exerted at the transcriptional, translational and post-translational level”
BackgroundAutophagy facilitates glycolysis during Ras-mediated oncogenic transformation
Lock, R., Roy, S., Kenific, C. M., Su, J. S., Salas, E., Ronen, S. M., & Debnath, J. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-06-0500 · Cited by 467
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467 · cited 1×
“Phosphorylation of oncogenic KRAS by protein kinase C (PKC) promotes translocation to the mitochondria and induces apoptosis in a BCL-X L -dependent manne”
BackgroundLei, K., Nimnual, A., Zong, W.-X., Kennedy, N. J., Flavell, R. A., Thompson, C. B., Bar-Sagi, D., & Davis, R. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4929-4942.2002 · Cited by 463
Self-citationVermeulen, K., Berneman, Z. N., & Van Bockstaele, D. R. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00267.x · Cited by 461
Fibronectin, integrins, and growth control
Danen, E. H. J., & Yamada, K. M. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1137 · Cited by 456 · cited 1×
“Prostate 6% (558) 8% (1,184) 2% (588) 156 24.”
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
The dark side of Ras: regulation of apoptosis
Cox, A. D., & Der, C. J. (2003) · Oncogene · doi:10.1038/sj.onc.1207111 · Cited by 437
Westwick, J. K., Lambert, Q. T., Clark, G. J., Symons, M., Van Aelst, L., Pestell, R. G., & Der, C. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1324 · Cited by 436 · cited 1×
“Although initial studies attributed the stimulation of cyclin D1 transcription by oncogenic RAS to the activation of the RAF–MAPK pathway, it has become evident that additional levels of control are executed through RAS activation of PI3Ks, the RHO family GTPase RAC1, and the RAL-guanine nucleotide dissociation stimul…”
BackgroundMultiple Ras Effector Pathways Contribute to G1Cell Cycle Progression
Gille, H., & Downward, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.22033 · Cited by 409
Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer
Yalcin, A., Telang, S., Clem, B., & Chesney, J. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.003 · Cited by 405
Feramisco, J. R., Gross, M., Kamata, T., Rosenberg, M., & Sweet, R. W. (1984) · Cell · doi:10.1016/0092-8674(84)90531-2 · Cited by 389 · cited 1×
“Indeed, soon after the identification of RAS, pioneering studies revealed that overexpression of oncogenic HRAS is sufficient for driving the entry of G0 phase -arrested cells into the cell cycle in the absence of growth factor”
BackgroundNational Cancer Institute (2020) · Definitions · doi:10.32388/f3vp5p · Cited by 383
Finco, T. S., Westwick, J. K., Norris, J. L., Beg, A. A., Der, C. J., & Baldwin, A. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24113 · Cited by 375
Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein
Stacey, D. W., & Kung, H.-F. (1984) · Nature · doi:10.1038/310508a0 · Cited by 370 · cited 1×
“Indeed, soon after the identification of RAS, pioneering studies revealed that overexpression of oncogenic HRAS is sufficient for driving the entry of G0 phase -arrested cells into the cell cycle in the absence of growth factor”
BackgroundPerturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements
Ramanathan, A., Wang, C., & Schreiber, S. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502267102 · Cited by 357
Identification of a Novel Ras-Regulated Proapoptotic Pathway
Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X.-F., Seed, B., & Avruch, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00683-8 · Cited by 357 · cited 1×
“On overexpression, these proteins are found in a pre-existing complex with mammalian STE20-like protein kinase 1 (MST1; also known as STK4), which is an enhancer of caspase 3 activation, and co-transfection of oncogenic RAS results in increased binding of active RAS to this complex and increased apoptosi”
BackgroundGum, R., Lengyel, E., Juarez, J., Chen, J. H., Sato, H., Seiki, M., & Boyd, D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10672 · Cited by 345
rac1 Regulates a Cytokine-Stimulated, Redox-Dependent Pathway Necessary for NF-κB Activation
Sulciner, D. J., Irani, K., Yu, Z.-X., Ferrans, V. J., Goldschmidt-Clermont, P., & Finkel, T. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.7115 · Cited by 339
Buerger, H., Otterbach, F., Simon, R., Poremba, C., Diallo, R., Decker, T., Riethdorf, L., Brinkschmidt, C., Dockhorn-Dworniczak, B., & Boecker, W. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<396::aid-path286>3.0.co;2-l · Cited by 328
The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance
Mayo, M. W., & Baldwin, A. S. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00002-0 · Cited by 324
Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer
Subbaramaiah, K., Norton, L., Gerald, W., & Dannenberg, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111415200 · Cited by 317
Milanini, J., Viñals, F., Pouysségur, J., & Pagès, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18165 · Cited by 315
Kompier, L. C., Lurkin, I., van der Aa, M. N. M., van Rhijn, B. W. G., van der Kwast, T. H., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013821 · Cited by 315
Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Induction of cyclin D1 overexpression by activated ras.
Filmus, J., Robles, A. I., Shi, W., Wong, M. J. H., Colombo, L. L., & Conti, C. J. (1994) · PubMed · Cited by 295
The RASSF proteins in cancer; from epigenetic silencing to functional characterization
Richter, A. M., Pfeifer, G. P., & Dammann, R. H. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.004 · Cited by 295 · cited 1×
“Additional RAS-regulated molecules with a role in pro-apoptotic programmes include RASSF1 and NORE1 (also known as RASSF5”
BackgroundZondag, G. C. M., Evers, E. E., ten Klooster, J. P., Janssen, L., van der Kammen, R. A., & Collard, J. G. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.4.775 · Cited by 289
Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis
Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J., & Clark, G. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000463200 · Cited by 289 · cited 1×
“On overexpression, these proteins are found in a pre-existing complex with mammalian STE20-like protein kinase 1 (MST1; also known as STK4), which is an enhancer of caspase 3 activation, and co-transfection of oncogenic RAS results in increased binding of active RAS to this complex and increased apoptosi”
BackgroundRak, J. W., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria‐Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., & Kerbel, R. S. (2000) · PubMed · Cited by 288
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287 · cited 1×
“RAS activation has also been shown to induce the destabilization of E-cadherin–β-catenin complexes and the relocalization of β-cateni”
BackgroundIdentification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases
Milanini-Mongiat, J., Pouysségur, J., & Pagès, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201753200 · Cited by 287
An elaborate pathway required for Ras-mediated epigenetic silencing
Gazin, C., Wajapeyee, N., Gobeil, S., Virbasius, C.-M., & Green, M. R. (2007) · Nature · doi:10.1038/nature06251 · Cited by 282
Dormond, O., Foletti, A., Paroz, C., & Rüegg, C. (2001) · Nature Medicine · doi:10.1038/nm0901-1041 · Cited by 281 · cited 1×
“Thyroid 3% (4,137) 2% (5,166) 8% (4,662) 11 0.”
Liu, J.-J., Chao, J.-R., Jiang, M.-C., Ng, S.-Y., Yen, J. J.-Y., & Yang-Yen, H.-F. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3654 · Cited by 275
Oncogenic Ras and its role in tumor cell invasion and metastasis
Campbell, P. M., & Der, C. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.015 · Cited by 275 · cited 1×
“Finally, oncogenic RAS directly contributes to the enhanced motility of cancer cells by affecting pronounced changes in the polymerization, organization and contraction of actin; the polymerization and/or stability of microtubules; and the transcriptional regulation of mitogenic gene product”
BackgroundK-ras activation generates an inflammatory response in lung tumors
Ji, H., Houghton, A. M., Mariani, T. J., Perera, S., Kim, C. B., Padera, R., Tonon, G., McNamara, K., Marconcini, L. A., Hezel, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209237 · Cited by 271
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20476 · Cited by 270
(2001) · PubMed · Cited by 270
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
Fang, X., Yu, S., Eder, A., Mao, M., Bast, R. C., Boyd, D., & Mills, G. B. (1999) · Oncogene · doi:10.1038/sj.onc.1203076 · Cited by 266
Analysis of the transcriptional program induced by Raf in epithelial cells
Schulze, A., Lehmann, K., Jefferies, H. B. J., McMahon, M., & Downward, J. (2001) · Genes & Development · doi:10.1101/gad.191101 · Cited by 259
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253
RAS pathways to cell cycle control and cell transformation
Pellicer, A. (1998) · Frontiers in Bioscience · doi:10.2741/a331 · Cited by 248
Allosteric modulation of Ras positions Q61 for a direct role in catalysis
Buhrman, G., Holzapfel, G., Fetics, S., & Mattos, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912226107 · Cited by 245 · cited 2×
“Skin 6% (2,100) 3% (1,462) 18% (4,956) 22.”
DuPage, M., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R., Schmidt, L. M., Crowley, D., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244 · cited 1×
“This concept is supported by recent experimental evidence from a mouse model of oncogenic KRAS G12D -induced lung cancer, demonstrating that the initial immune response becomes substantially attenuated, eventually leading to a full escape from immune surveillanc”
BackgroundXie, W., & Herschman, H. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31742 · Cited by 240
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Heese, C., & Pedersen, P. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22776 · Cited by 231
Recurrent KRAS codon 146 mutations in human colorectal cancer
Edkins, S., & O’Meara, S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3251 · Cited by 229 · cited 1×
“Lung 0% (2,091) 17% (16,348) 1% (3,081) 62 52.”
Glucose Catabolism in Cancer Cells.
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16918 · Cited by 229
Involvement of Autophagy in Oncogenic K-Ras-induced Malignant Cell Transformation
Kim, M.-J., Woo, S.-J., Yoon, C.-H., Lee, J.-S., An, S., Choi, Y.-H., Hwang, S.-G., Yoon, G., & Lee, S.-J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.138958 · Cited by 227
MAP Kinases and Hypoxia in the Control of VEGF Expression
Berra, E., Pagès, G., & Pouysségur, J. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026506011458 · Cited by 223
Role of Ras Signaling in the Induction of Snail by Transforming Growth Factor-β
Horiguchi, K., Shirakihara, T., Nakano, A., Imamura, T., Miyazono, K., & Saitoh, M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804777200 · Cited by 219 · cited 1×
“Thus, the expression of oncogenic RAS reduces the levels of E-cadherin through the upregulation of the E-cadherin transcriptional repressors SNAIL (also known as SNAI1) and SLUG (also known as SNAI2), the stimulation of E-cadherin proteolytic degradation and the induction of E-cadherin promoter methylatio”
BackgroundZabrenetzky, V., Harris, C. C., Steeg, P. S., & Roberts, D. D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590209 · Cited by 219 · cited 1×
“Oncogenic RAS can also promote the angiogenic process by restricting the expression of negative regulators of neo-vascularization, such as thrombospondin 1 (TSP1; also known as THBS1) and TSP2 (also known as THBS2), in tumour cell”
BackgroundRobles, A. I., Rodriguez-Puebla, M. L., Glick, A. B., Trempus, C., Hansen, L., Sicinski, P., Tennant, R. W., Weinberg, R. A., Yuspa, S. H., & Conti, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.16.2469 · Cited by 217 · cited 1×
“As such, cyclin D1-deficient mice are resistant to developing mammary cancers and squamous tumours that are induced by the HRAS oncogen”
BackgroundFrequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.
Capella, G., Cronauer-Mitra, S., Pienado, M. A., & Perucho, M. (1991) · Environmental Health Perspectives · doi:10.1289/ehp.9193125 · Cited by 214
Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211
Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 210
The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle.
Denko, N. C., Giaccia, A. J., Stringer, J. R., & Stambrook, P. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5124 · Cited by 209 · cited 1×
“Conversely, in cells that are deficient in DNA damage checkpoints (through the loss of p53, for example) deregulated DNA replicative activity that is induced by oncogenic RAS results in the generation of chromosome aberrations such as dicentric chromosomes, acentric chromosomes and double-minute chromosomes, leading t…”
BackgroundFeng, Y., Santoriello, C., Mione, M., Hurlstone, A., & Martin, P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000562 · Cited by 206
Inhibition of Angiogenesis by Thrombospondin-2
Volpert, O. V., Tolsma, S. S., Pellerin, S., Feige, J. J., Chen, H., Mosher, D. F., & Bouck, N. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2780 · Cited by 201 · cited 1×
“In addition, they directly affect the viability of endothelial cell”
BackgroundSp1 Phosphorylation by Erk 2 Stimulates DNA Binding
Merchant, J. L., Du, M., & Todisco, A. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9964 · Cited by 199
Kevil, C. G., De Benedetti, A., Payne, D. K., Coe, L. L., Laroux, F. S., & Alexander, J. S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960315)65:6<785::aid-ijc14>3.0.co;2-3 · Cited by 199
Regulation of the cell cycle machinery by oncogenic ras.
Winston, J. T., Coats, S., Wang, Y.-Z., & Pledger, W. J. (1996) · PubMed · Cited by 198
The tumor suppressor RASSF1A in human carcinogenesis: an update.
Dammann, R., Schagdarsurengin, U., Seidel, C., Strunnikova, M., Rastetter, M., Baier, K., & Pfeifer, G. P. (2005) · PubMed · doi:10.14670/hh-20.645 · Cited by 197
McCarthy, S. A., Samuels, M. L., Pritchard, C. A., Abraham, J. A., & McMahon, M. (1995) · Genes & Development · doi:10.1101/gad.9.16.1953 · Cited by 193 · cited 1×
“Adding to its function as a transducer of growth factor signalling, active RAS can also enhance the proliferative capacity of cells by inducing the transcriptional upregulation of growth factors such as heparin-binding epidermal growth factor-like growth factor (HBEGF), transforming growth factor-α (TGFα) and amphireg…”
BackgroundFood groups and risk of squamous cell esophageal cancer in Northern Italy
Bosetti, C., Vecchia, C. L., Talamini, R., Simonato, L., Zambon, P., Negri, E., Trichopoulos, D., Λάγιου, Π., Bardini, R., & Franceschi, S. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000715)87:2<253::aid-ijc17>3.0.co;2-a · Cited by 191
Brembeck, F. H., Schreiber, F. S., Deramaudt, T. B., Craig, L. E., Rhoades, B., Swain, G. P., Grippo, P. J., Stoffers, D. A., Silberg, D. G., & Rustgi, A. K. (2003) · PubMed · Cited by 190
Westwick, J. K., Cox, A. D., Der, C. J., Cobb, M. H., Hibi, M., Karin, M., & Brenner, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6030 · Cited by 187
Scheidig, A. J., Burmester, C., & Goody, R. S. (1999) · Structure · doi:10.1016/s0969-2126(00)80021-0 · Cited by 187 · cited 1×
“Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.”
BackgroundSheng, H., Williams, C. S., Shao, J., Liang, P., DuBois, R. N., & Beauchamp, R. D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.22120 · Cited by 186
ETS transcription factors: Possible targets for cancer therapy
Oikawa, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03320.x · Cited by 184
Takuwa, N., Fukui, Y., & Takuwa, Y. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1346 · Cited by 182
Clark, C. E., Beatty, G. L., & Vonderheide, R. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.037 · Cited by 181
Ras caught in another affair: the exchange factors for Ral
Wolthuis, R. M. F., & Bos, J. L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80016-1 · Cited by 180
Blum, R., Jacob‐Hirsch, J., Amariglio, N., Rechavi, G., & Kloog, Y. (2005) · PubMed · Cited by 178
Muschel, R. J., Williams, J. E., Lowy, D. R., & Liotta, L. A. (1985) · PubMed · Cited by 175
Development and Disease in Proteinase-Deficient Mice
Carmeliet, P., & Collen, D. (1998) · Thrombosis Research · doi:10.1016/s0049-3848(98)00122-4 · Cited by 175
Suppression of Ras-Induced Apoptosis by the Rac GTPase
Joneson, T., & Bar-Sagi, D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5892 · Cited by 174
Self-citationSemenza, G. L. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9058-y · Cited by 169
Detection of K-ras mutations in lung carcinomas: Relationship to prognosis
(1996) · Lung Cancer · doi:10.1016/s0169-5002(96)80041-9 · Cited by 168
Stimulation of angiogenesis by Ras proteins
Kranenburg, O., Gebbink, M. F. B. G., & Voest, E. E. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.09.004 · Cited by 168 · cited 1×
“The mechanisms by which RAS activation initiates and sustains pro-angiogenic processes are complex and impinge on the modulation of levels of endothelial growth factors and also increase local inflammation and stromal remodellin”
BackgroundBlum, R., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., & Kloog, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.999.65.3 · Cited by 161
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
Peli, J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1824 · Cited by 159
Braga, V. M. M., Betson, M., Li, X., & Lamarche-Vane, N. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.11.3703 · Cited by 158
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
Li, Q., Haigis, K. M., McDaniel, A., Harding-Theobald, E., Kogan, S. C., Akagi, K., Wong, J. C. Y., Braun, B. S., Wolff, L., Jacks, T., et al. (2011) · Blood · doi:10.1182/blood-2010-04-280750 · Cited by 154
Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells.
Kinoshita, T., Yokota, T., Arai, K., & Miyajima, A. (1995) · PubMed · Cited by 148
Potenza, N., Vecchione, C., Notte, A., Rienzo, A. D., Rosica, A., Bauer, L., Affuso, A., Felice, M. D., Russo, T., Poulet, R., et al. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400397 · Cited by 145 · cited 1×
“Notably, a substitution of HRAS for KRAS in a knock-in model rescues the embryonic lethality that is caused by the loss of KRAS4B , thus implying a functional overlap between the two isoforms when expressed from the wild-type allel”
BackgroundSuppression of Ras-stimulated transformation by the JNK signal transduction pathway
Kennedy, N. J., Sluss, H. K., Jones, S. N., Bar-Sagi, D., Flavell, R. A., & Davis, R. J. (2003) · Genes & Development · doi:10.1101/gad.1062903 · Cited by 141 · cited 1×
“, and HRAS Q61L -mediated activation of JUN N-terminal kinase (JNK) signalling has also been associated with a pro-apoptotic rol”
BackgroundSelf-citationSeidler, B., Schmidt, A., Mayr, U., Nakhai, H., Schmid, R. M., Schneider, G., & Saur, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800487105 · Cited by 136
Rosen, K., Rak, J., Leung, T., Dean, N. M., Kerbel, R. S., & Filmus, J. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.2.447 · Cited by 135 · cited 1×
“Oncogenic RAS is also thought to contribute to the capacity of tumour cells to migrate through the circulatory system by protecting them from matrix deprivation-induced apoptosis, or anoiki”
BackgroundRas-dependent carbon metabolism and transformation in mouse fibroblasts
Chiaradonna, F., Sacco, E., Manzoni, R., Giorgio, M., Vanoni, M., & Alberghina, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209528 · Cited by 131
Tyner, J. W., Erickson, H., Deininger, M. W. N., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., et al. (2009) · Blood · doi:10.1182/blood-2008-04-152157 · Cited by 131 · cited 1×
“A new perspective on the issue of the contributions of particular amino acid substitutions to the in vivo transforming capabilities of RAS has been added by recent findings that have documented previously uncharacterized RAS mutations in colorectal tumours and leukaemia”
Woods, D., Cherwinski, H., Venetsanakos, E., Bhat, A., Gysin, S., Humbert, M., Bray, P. F., Saylor, V. L., & McMahon, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3192-3205.2001 · Cited by 131
Vitale-Cross, L., Amornphimoltham, P., Fisher, G., Molinolo, A. A., & Gutkind, J. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2623 · Cited by 129
Transcriptional Regulation of the Cyclooxygenase-2 Gene in Activated Mast Cells
Reddy, S. T., Wadleigh, D. J., & Herschman, H. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3107 · Cited by 128
Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors
Rocks, O., Lorentzen, A., & Bastiaens, P. I. H. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.06.007 · Cited by 127
Pollock, C. B., Shirasawa, S., Sasazuki, T., Kolch, W., & Dhillon, A. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1911 · Cited by 127
Microinjection of transforming ras protein induces c-fos expression.
Stacey, D. W., Watson, T., Kung, H. F., & Curran, T. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.1.523 · Cited by 126
Ras acylation, compartmentalization and signaling nanoclusters (Review)
Henis, Y. I., Hancock, J. F., & Prior, I. A. (2009) · Molecular Membrane Biology · doi:10.1080/09687680802649582 · Cited by 126 · cited 1×
“At the subcellular level, RAS proteins have been shown to reside in distinct compartments within the cell, with each compartment eliciting differential signalling outputs that may control various aspects of oncogenic transformatio”
BackgroundShapiro, R. L., Duquette, J. G., Roses, D. F., Nunes, I., Harris, M. N., Kamino, H., Wilson, E. L., & Rifkin, D. B. (1996) · PubMed · Cited by 125
Inflammation and cancer: The oncogene-driven connection
Borrello, M. G., Degl’Innocenti, D., & Pierotti, M. A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.060 · Cited by 123
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia
Perentesis, J. P., Bhatia, R., Boyle, E., Shao, Y., Shu, X., Steinbuch, M., Sather, H. N., Gaynon, P. S., Kiffmeyer, W. R., Envall-Fox, J., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403272 · Cited by 118
Gangarosa, L. M., Sizemore, N., Graves-Deal, R., Oldham, S. M., Der, C. J., & Coffey, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18926 · Cited by 118 · cited 1×
“Adding to its function as a transducer of growth factor signalling, active RAS can also enhance the proliferative capacity of cells by inducing the transcriptional upregulation of growth factors such as heparin-binding epidermal growth factor-like growth factor (HBEGF), transforming growth factor-α (TGFα) and amphireg…”
BackgroundKras regulatory elements and exon 4A determine mutation specificity in lung cancer
To, M. D., Wong, C. E., Karnezis, A. N., Del Rosario, R., Di Lauro, R., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis
Mo, L., Zheng, X., Huang, H.-Y., Shapiro, E., Lepor, H., Cordon-Cardo, C., Sun, T.-T., & Wu, X.-R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30062 · Cited by 116
Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E
Esteve-Puig, R., Canals, F., Colomé, N., Merlino, G., & Recio, J. Á. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004771 · Cited by 115
K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts
Vizan, P., Boros, L. G., Figueras, A., Capella, G., Mangues, R., Bassilian, S., Lim, S., Lee, W.-N. P., & Cascante, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0074 · Cited by 115
Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway
Tidyman, W. E., & Rauen, K. A. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000902 · Cited by 110
Al-Mulla, F., Milner-White, E. J., Going, J. J., & Birnie, G. D. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<433::aid-path273>3.0.co;2-e · Cited by 110
Dajee, M., Tarutani, M., Deng, H., Cai, T., & Khavari, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205287 · Cited by 104
Rivard, N., Boucher, M.-J., Asselin, C., & L’Allemain, G. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.4.c652 · Cited by 100
Oncogenic Ras Sensitizes Cells to Apoptosis by Par-4
Nalça, A., Qiu, S. G., El-Guendy, N., Krishnan, S., & Rangnekar, V. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.29976 · Cited by 98 · cited 1×
“RAF contributes to RAS-induced suppression of apoptosis by the downregulation of the pro-apoptotic transcriptional repressor prostate apoptosis response 4 (PAR4; also known as PAWR”
BackgroundRas regulation of DNA-methylation and cancer
Patra, S. K. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.01.012 · Cited by 93 · cited 1×
“There is an indication that such a pro-apoptotic function of RAS might be selected against in cancer, as the expression of either RASSF1 or RASSF5 in tumours is frequently suppressed either owing to promoter hypermethylation or — in the case of RASSF1 — owing to the deletion of the chromosomal region that contains the…”
BackgroundKnauf, J. A., Ouyang, B., Knudsen, E. S., Fukasawa, K., Babcock, G., & Fagin, J. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511690200 · Cited by 92 · cited 1×
“The documented capacity of oncogenic HRAS G12V to induce accelerated transition through G2/M, to inhibit the activation of the G2 DNA damage checkpoint, as well as to induce defects in mitotic spindle checkpoint”
BackgroundOncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics
Ancrile, B. B., O'Hayer, K. M., & Counter, C. M. (2008) · Molecular Interventions · doi:10.1124/mi.8.1.6 · Cited by 92
Seliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampé, R., & Huber, C. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<122::aid-immu122>3.0.co;2-f · Cited by 91 · cited 1×
“Indeed, transformation by RAS reduced the levels and functionality of the antigen peptide transporters TAP1 and TAP2 and proteasome subunits LMP2 (also known as PSMB9) and LMP7 (also known as PSMB8), resulting in decreased MHC expressio”
BackgroundOncogenes and tumor angiogenesis
Rak, J. W., & Yu, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.014 · Cited by 90
Filmus, J., Zhao, J., & Buick, R. (1992) · PubMed · Cited by 86
Bar-Sagi, D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1441-1443.2001 · Cited by 85 · cited 1×
“Earlier attempts to delineate the functional diversity of different oncogenic RAS isoforms mainly relied on the use of ectopic overexpression approache”
BackgroundSelf-citationExperimental metastatic ability of H-ras-transformed NIH3T3 cells.
Bondy, G. P., Wilson, S. M., & Chambers, A. F. (1985) · PubMed · Cited by 82
Costello, R. T., Mallet, F., Sainty, D., Maraninchi, D., Gastaut, J.-A., & Olive, D. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<90::aid-immu90>3.0.co;2-5 · Cited by 81
Sers, C., Kuner, R., Falk, C. S., Lund, P., Sueltmann, H., Braun, M., Buness, A., Ruschhaupt, M., Conrad, J., Mang‐Fatehi, S., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24557 · Cited by 80 · cited 1×
“The oncogenic RAS-mediated downregulation of MHC was shown to be independent of the promoter activity at MHC loci, suggesting that defects in the components of antigen-processing machinery could be responsible for the compromised antigenic peptide transport and loadin”
BackgroundA Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
Granville, C. A., Memmott, R. M., Balogh, A., Mariotti, J., Kawabata, S., Han, W., LoPiccolo, J., Foley, J., Liewehr, D. J., Steinberg, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005061 · Cited by 80 · cited 1×
“Salivary gland 15% (161) 3% (170) 0% (45) NA NA”
Lengyel, E. R., Stepp, E., Gum, R. J., & Boyd, D. D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.39.23007 · Cited by 80
Rosen, K. V., Rak, J. W., Jin, J., Kerbel, R. S., Newman, M. J., & Filmus, J. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00564-7 · Cited by 78
Delp, K., Momburg, F., Hilmes, C., Huber, C. G., & Seliger, B. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702363 · Cited by 77 · cited 2×
“Oesophagus 1% (161) 4% (375) 0% (161) 4.”
Fujimoto, K., Sheng, H., Shao, J., & Beauchamp, R. D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5229 · Cited by 75 · cited 1×
“RAS activation has also been shown to induce the destabilization of E-cadherin–β-catenin complexes and the relocalization of β-cateni”
BackgroundThang, N. N. T., Derouazi, M., Philippin, G., Arcidiaco, S., Berardino-Besson, W. D., Masson, F., Hoepner, S., Riccadonna, C., Burkhardt, K., Guha, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3074 · Cited by 73 · cited 1×
“One possible mechanism by which oncogenic RAS expression may lead to a compromised antitumour immune response is through the recruitment of immunosuppressive regulatory T cells (T Regs ) and myeloid-derived suppressor cells (MDSCs) to the tumour sit”
BackgroundBrodsky, S. V., Chen, J., Lee, A., Akassoglou, K., Norman, J. T., & Goligorsky, M. S. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.4.h1784 · Cited by 68
Modulation of the immune response and tumor growth by activated Ras
Weijzen, S., Velders, M. P., & Kast, W. M. (1999) · Leukemia · doi:10.1038/sj.leu.2401367 · Cited by 67
Jiang, Y., & Muschel, R. J. (2002) · PubMed · Cited by 66
Control of colorectal metastasis formation by K-Ras
Smakman, N., Rinkes, I. H. M. B., Voest, E. E., & Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.07.001 · Cited by 66 · cited 1×
“The perturbation of cell–cell contacts by oncogenic RAS is accomplished through the targeting of the molecular machinery that maintains intercellular adhesion junctions, which includes the calcium-dependent E-cadherin receptor and its associated cytoplasmic protein β-cateni”
Background
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
“The proteins encoded by these genes are extremely homologous, and they belong to the small guanosine triphosphate (GTP)-binding protein (G protein) superfamily [46].”
BackgroundTargeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Vyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.